2005
A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma
Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005, 106: 454-457. PMID: 15811959, DOI: 10.1182/blood-2004-11-4570.Peer-Reviewed Original ResearchConceptsRefractory cutaneous T-cell lymphomaCutaneous T-cell lymphomaPhase 1 trialT-cell lymphomaDenileukin diftitoxInterleukin-2High-affinity IL-2 receptorGrade 4 lymphopeniaLeukemia cellsIL-2R expressionIL-2 receptorT-cell leukemia cellsCD25 expressionIL-2RVivo upregulationP75 subunitDiftitoxGrade 2BexaroteneLow dosesPatientsLymphoma cellsBiomodulatory effectDiphtheria toxinLymphoma
2003
Interleukin-2 receptor–directed therapies for cutaneous lymphomas
Foss FM, Waldmann TA. Interleukin-2 receptor–directed therapies for cutaneous lymphomas. Hematology/Oncology Clinics Of North America 2003, 17: 1449-1458. PMID: 14710895, DOI: 10.1016/s0889-8588(03)00110-2.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalClinical Trials as TopicDiphtheria ToxinDrug Delivery SystemsGene Expression Regulation, NeoplasticHumansImmunoconjugatesImmunotherapyImmunotoxinsInterleukin-2Lymphoma, T-Cell, CutaneousNeoplasm ProteinsProtein IsoformsProtein SubunitsReceptors, Interleukin-2Recombinant Fusion ProteinsRetinoidsSkin NeoplasmsConceptsT-cell lymphomaIL-2RIL-2/IL-2R systemPeripheral T-cell lymphomaAnaplastic large cell lymphomaNatural killer lymphomaReceptor-directed therapyIL-2R systemIL-2 receptorLarge cell lymphomaRational therapeutic strategiesIL-2R subunitsCutaneous lymphomasSpecific immunotherapyIL-2Cell lymphomaTherapeutic strategiesLymphomaHumanized antibodyCTCLBeta-emitting radionuclidesAntibodiesImmunotherapyTherapyAgents
2002
Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene
Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM. Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene. Leukemia Research 2002, 26: 1077-1083. PMID: 12443879, DOI: 10.1016/s0145-2126(02)00059-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArginineButyratesCell SurvivalCyclic AMPDiphtheria ToxinDose-Response Relationship, DrugDrug SynergismHumansInterleukin-2Interleukin-2 Receptor beta SubunitLeukemiaLymphomaReceptors, InterleukinReceptors, Interleukin-2Recombinant Fusion ProteinsResponse ElementsSecond Messenger SystemsUp-RegulationConceptsCutaneous T-cell lymphomaIL-2R expressionNon-Hodgkin lymphomaArginine butyrateIL-2RLow affinity IL-2RHistone deacetylaseDirect growth-inhibitory effectB-cell non-Hodgkin lymphomaHigh-affinity IL-2 receptorLeukemia cellsCAMP response elementT-cell lymphomaIL-2 receptorNative diphtheria toxinGrowth inhibitory effectsClinical trialsP75 subunitAchievable concentrationsResponse rateVitro dataDAB389IL-2Interleukin-2 geneTumor cellsLymphoma cellsImmunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox
Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood 2002, 100: 1399-1403. PMID: 12149223, DOI: 10.1182/blood-2002-01-0300.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAlitretinoinAntineoplastic AgentsB-LymphocytesBexaroteneDiphtheria ToxinGene Expression RegulationHumansInterleukin-2Leukemia-Lymphoma, Adult T-CellLeukemia, Lymphocytic, Chronic, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Interleukin-2Receptors, Retinoic AcidRecombinant Fusion ProteinsRetinoid X ReceptorsRetinoidsT-LymphocytesTetrahydronaphthalenesTranscription FactorsTretinoinTumor Cells, CulturedConceptsRetinoic acid receptorsImmunomodulatory effectsIL-2RHigh affinity IL-2R expressionCutaneous T-cell lymphomaHigh affinity IL-2R.Interleukin-2 receptor expressionIL-2R expressionT-cell lymphomaB cell leukemia cellsB-cell leukemiaT-cell leukemiaMechanism of actionAutoimmune diseasesHematologic malignanciesClinical activityReceptor expressionLymphoid malignanciesIL-2R.Retinoid X receptor (RXR) familyP75 subunitAcid receptorsRexinoid receptorsLeukemia cellsRexinoids